Osanetant

Osanetant is a drug that acts as a selective, non-peptide antagonist at the neurokinin 1 receptor (NK1R). It was developed by Sanofi-Aventis but was discontinued for unknown reasons.

Pharmacology

Osanetant is a selective, non-peptide antagonist at the NK1R. This receptor is a G-protein coupled receptor located in various tissues, including the central nervous system. It is involved in various biological functions, including pain perception, mood regulation, and immune response. By blocking this receptor, osanetant can potentially modulate these functions.

Development and Clinical Trials

Osanetant was developed by the pharmaceutical company Sanofi-Aventis. It underwent clinical trials for the treatment of various conditions, including schizophrenia, anxiety disorders, and depression. However, the development of osanetant was discontinued for unknown reasons.

Potential Therapeutic Uses

Despite the discontinuation of its development, osanetant has potential therapeutic uses. Its ability to block the NK1R makes it a potential candidate for the treatment of conditions associated with this receptor. These include various psychiatric disorders, such as schizophrenia and depression, as well as pain conditions.

See Also

• Neurokinin 1 receptor
• Sanofi-Aventis
• Schizophrenia
• Anxiety disorders
• Depression

Osanetant

• 
  Osanetant
• 
  Osanetant synthesis (Glaxo)
• 
  Osanetant synthesis (Warner Lambert)
• 
  Osanetant